The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients

The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our expectation was a 20 % decrease in drug cravings from baseline to end-point.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Chemically-Induced Disorders Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders Substance Use Disorders Substance-Related Disorders

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Centre de recherche Fernand-Seguin

Montreal, Quebec, H1N 3V2, Canada

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with as schizophrenia spectrum disorder
Patients with a comorbid substance use disorder

Exclusion criteria

Patients already on quetiapine or clozapine
Patients hospitalized or acutely ill
Total score lower than 65 on the PANSS
Pregnancy
Female subjects of childbearing potential without adequate contraception
Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.

Treatment and study plan

Quetiapine (drug)

Drug

Sponsors and collaborators

Lead sponsor

Université de Montréal

Other

Collaborators

AstraZeneca

Registry information

Important dates

First posted: Feb 23, 2006
Registry last updated: Feb 23, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed